Introducción: el lupus es una enfermedad compleja y varias veces de difícil abordaje. Alcanzar la remisión es uno de los objetivos, incorporando opciones terapéuticas. Objetivos: describir las características generales de los pacientes según el estado de la enfermedad y el uso de belimumab. Materiales y métodos: estudio de corte transversal, registro RELESSAR. Se definió el estado de la enfermedad como: remisión: SLEDAI=0 y sin corticoides; baja actividad de la enfermedad: SLEDAI >0 y ≤4 y sin corticoides; control no óptimo: SLEDAI >4 y cualquier dosis de corticoides. Resultados: se incluyeron 1.277 pacientes, 23,4% en remisión, 12,6% en baja actividad y 63,8% con control no óptimo. En este último grupo eran más jóvenes y con menor duración de la enfermedad; presentaban mayores índices de actividad y cronicidad, y mayor empleo de inmunosupresores. Solo el 22,3% de los pacientes con criterio potencial de uso de belimumab (lupus eritematoso sistémico activo a pesar del tratamiento estándar) lo recibía en ese momento. Las variables asociadas a hospitalizaciones fueron: terapia con corticoides, ciclofosfamida y mayor SLICC. Conclusiones: se refleja la complejidad del manejo de estos pacientes y se visualizan aspectos estructurales como la desigualdad. El uso del belimumab resultaría beneficioso en los pacientes seleccionados.
Introduction: lupus is a complex disease and often difficult to approach. Achieving remission is one of the objectives, incorporating therapeutic options. Objectives: to describe the characteristics of the patients and the use of belimumab, according to the status of the disease. Materials and methods: cross-sectional study. Patients of the RELESSAR registry. Stratification: Remission: SLEDAI=0 and without corticosteroids. Low disease activity SLEDAI> 0 and ≤4 and without corticosteroids and non-optimal control: SLEDAI> 4 and any dose of corticosteroids. Results: a total of 1,277 patients were included, 23.4% in remission, 12.6% in low disease activity and 63.8% in non-optimal control. The last group was younger and had a shorter duration of the disease. They had higher activity and chronicity indices and greater use of immunosuppressants. Only 22.3% of the patients with potential criteria for the use of belimumab (activity disease despite standard treatment) were receiving it. The variables associated with hospitalizations were: corticosteroids, cyclophosphamide and higher SLICC. Those associated with severe infection: mycophenolate mofetil, azathioprine, corticosteroids, and higher SLICC. Conclusions: the complexity of the management of these patients is reflected, visualizing structural aspects such as inequality. The use of belimumab could be beneficial in selected patients.
Humans , Lupus Erythematosus, Systemic , Referral and Consultation , Therapeutics
OBJECTIVES: To explore the prevalence of the ultrasound (US) findings of enthesitis in a group of healthy subjects. METHODS: US assessments of quadriceps, patellar and Achilles tendons, and plantar fascia entheses were performed by a rheumatologist on 82 healthy volunteers focusing on the US findings indicative of "active" inflammation according to the Outcome Measures in Rheumatology (OMERACT) definitions. RESULTS: Eight hundred and twenty entheses were evaluated in 82 healthy subjects. One or more US findings of "active" inflammation were found in at least one enthesis in 30 out of 82 subjects (34.1%), in 69 out of 820 entheses (8.4%). Entheseal thickening, hypoechogenicity and PD signal were respectively found in at least one enthesis in 23 (28.0%), 11 (13.4%) and 8 (9.8%) out of 82 subjects. Among the 69 entheses showing US features of "active" inflammation, entheseal thickening, hypoechogenicity and PD signal were found as isolated in 61 entheses and in combination in the remaining 8 (entheseal thickening and hypoechogenicity). CONCLUSIONS: Our results show a relatively high prevalence of US findings of "active" inflammation at the lower limb entheses in a group of healthy subjects, thus questioning the discriminant power of the OMERACT definitions for the diagnosis of "active" enthesitis. A combination of grey-scale and PD findings at a specific threshold to be defined could improve both the reliability and clinical usefulness of US.
Arthritis/diagnostic imaging , Enthesopathy/diagnostic imaging , Ultrasonography , Healthy Volunteers , Humans , Lower Extremity/physiopathology , Prevalence , Reproducibility of Results , Severity of Illness Index
OBJECTIVES: To investigate the prevalence of the ultrasound findings indicative of monosodium urate crystal deposits at the hip joint in patients with gout and to explore the association between the ultrasound findings and the clinical and serological features. METHODS: Bilateral ultrasound assessment of the hip joint was carried out in 40 consecutive patients with gout, diagnosed according to the latest Gout American College of Rheumatology/European League Against Rheumatism classification criteria, and 25 disease controls. Ultrasound evidence of crystal deposits was obtained using the Outcome Measures in Rheumatology definitions: hip intra-articular aggregates and/or tophi, and "double contour" sign over the hyaline cartilage of the femoral head. RESULTS: The ultrasound examination revealed crystal deposits in at least one hip in 17 out of 40 patients (42.5%) with gout, and in 2 out of 25 disease controls (8.0%) (P = 0.0029). Aggregates, tophi, and "double contour" sign were found in at least one hip in 13 (32.5%), 6 (15.0%) and 6 (15.0%) out of 40 patients with gout, respectively. A moderate association between disease duration (P = 0.004, Rpb = 0.442), number of gouty "attacks" in the previous year (P = 0.029, Rpb = 0.346), presence of subcutaneous tophi (P = 0.037, V = 0.330) and ultrasound crystal deposits was found. CONCLUSION: Our results indicate that detecting monosodium urate crystals by ultrasound is common at hip joint in patients with gout.
Arthritis, Gouty/diagnosis , Hip Joint/diagnostic imaging , Ultrasonography/methods , Uric Acid/metabolism , Aged , Arthritis, Gouty/metabolism , Biomarkers/metabolism , Female , Hip Joint/metabolism , Humans , Male , Middle Aged , Reproducibility of Results
OBJECTIVES: To determine the prevalence of the ultrasound findings indicating monosodium urate crystal deposits at the popliteal groove region in patients with gout; to evaluate the diagnostic accuracy of ultrasound in detecting monosodium urate crystal deposits at the popliteal groove region, patellar tendon and the knee hyaline cartilage; to investigate the correlation between the ultrasound findings at the popliteal groove region and the clinical features. METHODS: Bilateral ultrasound assessment of the popliteal groove region, patellar tendon and femoral condyles' hyaline cartilage was performed on 47 consecutive patients with gout and 37 controls. The ultrasound findings indicating monosodium urate crystals (aggregates, tophi and "double-contour" sign) were identified according to the Outcome Measures in Rheumatology definitions. RESULTS: One or more ultrasound abnormalities (aggregates and/or tophi) were found in at least one popliteal groove region in 23 out of 47 patients with gout (48.9%) and in 4 out of 37 controls (10.8%) (P < 0.001). Sensitivity, specificity and diagnostic odds ratio of the ultrasound findings at the popliteal groove region, patellar tendon and at the femoral condyles' hyaline cartilage were 0.49/0.89/7.9, 0.62/0.81/6.9 and 0.30/1.0/32.0, respectively. There was a significant correlation between the ultrasound findings at the popliteal groove region and history of knee inflammatory involvement (P < 0.001, V = 0.644) and number of gouty "attacks" in the previous year (P = 0.012, V = 0.434). CONCLUSIONS: This study provides new insights into the ultrasound assessment of patients with gout, highlighting the clinical relevance of the popliteal groove region as an area of collection of otherwise undetectable monosodium urate crystals.
Arthritis, Gouty/diagnostic imaging , Femur/diagnostic imaging , Knee Joint/diagnostic imaging , Ultrasonography/methods , Uric Acid , Aged , Cartilage, Articular/diagnostic imaging , Female , Humans , Imaging, Three-Dimensional , Male , Middle Aged , Patellar Ligament/diagnostic imaging , Tomography, X-Ray Computed
The aim of this study was to evaluate the reliability of the outcome measures in rheumatology (OMERACT) definitions for ultrasound (US) elementary lesions in gout through an image reading exercise. Images from patients with gout (static images and videos) were collected. As an initial step, we carried out a image reading exercise within the experts of the Pan-American League of Associations for Rheumatology (PANLAR) US Study Group (n = 16). The following step consisted in a web-based exercise with the participation of larger number of sonographers (n = 63) from different centers. Images were rated evaluating the presence/absence of any US elementary lesion. Inter- and intra-reader reliabilities were analyzed using kappa coefficients. Participants were stratified according to their level of experience. In the first exercise, inter-reader kappa values were 0.45 for aggregates, 0.57 for tophus, 0.69 for erosions, and 0.90 for double contour (DC). Intra-reader kappa values were 0.86, 0.76, 0.80, and 0.90, respectively. The web-based exercise showed inter-reader kappa values for aggregates, tophus, erosions, and DC of 0.42, 0.49, 0.69, and 0.79, respectively. The intra-reader kappa values were 0.62, 0.69, 0.77, and 0.85, respectively. Reliability was not influenced by the sonographer's level of experience. The reliability of the new OMERACT US definitions for elementary lesions in gout ranged from moderate to excellent, depending on the type of lesion.
Gout/diagnostic imaging , Cross-Sectional Studies , Humans , Reproducibility of Results , Ultrasonography
OBJECTIVE: To preliminarily explore the diagnostic potential of ultrasound (US) in detecting calcium pyrophosphate (CPP) crystal deposits at the hip joint in a cohort of patients with CPP deposition disease (CPPD) who were previously evaluated by conventional radiography (CR) and to assess the sensitivity and specificity as well as the agreement between US and CR in the evaluation of hip CPP crystal deposits. METHODS: Fifty consecutive patients with definite CPPD and 40 age/sex/body mass index-matched disease control subjects who had undergone hip CR within the previous 6 months were enrolled. Bilateral hip US examination was carried out to assess the presence of CCP crystal deposits at the acetabular labrum fibrocartilage and at the femoral head's hyaline cartilage. Two independent radiologists evaluated the presence of hip CPP crystal deposits on CR in both groups. RESULTS: US findings indicative of CPP crystal deposits were found in at least 1 hip in 45 of 50 patients with CPPD (90.0%) and in 73 of 100 hips (73.0%). CPP crystal deposits were more frequently found at the acetabular labrum fibrocartilage than at the femoral head's hyaline cartilage (72% and 17% of the hips in patients with CPPD, respectively). US and CR sensitivity was 90% and 86%, whereas US and CR specificity was 85% and 90%, respectively. Total agreement between the US and CR findings was 77.8%. CONCLUSION: Our results provide new evidence supporting US as a first-line, sensitive, safe, and reliable imaging technique in detecting CPP crystal deposits at the hip level.
Calcium Pyrophosphate/metabolism , Cartilage, Articular/diagnostic imaging , Chondrocalcinosis/diagnosis , Hip Joint/diagnostic imaging , Ultrasonography/methods , Aged , Chondrocalcinosis/metabolism , Female , Hip Joint/metabolism , Humans , Male , Musculoskeletal System/diagnostic imaging , ROC Curve , Radiography/methods , Reproducibility of Results
Objetivo: el objetivo de nuestro estudio fue adaptar y validar el Indice Duruõz (ID) en una población argentina con esclerodermia. Métodos: Para la validación, reumatólogos tradujeron al español la versión original en francés. Para evaluar la validez constructiva se utilizó la escala global visual análoga del paciente (EVA), EVA para cada una de las preguntas de la misma actividad, el cuestionario de evaluación de salud (HAQ) y el Score modificado de Rodnan para evaluar la piel. Resultados: Se incluyeron 45 pacientes con diagnóstico de esclerodermia. La correlación entre la puntuación total de ID y el EVA global del paciente fue de 0,58, con el HAQ fue 0,63 y con el Rodnan fue 0,08. El coeficiente de correlación entre el EVA y cada grupo de preguntas para la misma actividad en el ID, indicó buena correlación para las preguntas que se refieren a las actividades de cocina, así como para vestirse, de higiene, y para las preguntas de oficina. Se encontró excelente nivel de correlación con los ítems relacionados con las actividades de motricidad fina. La reproducibilidad fue de 0,88 y la confiabilidad de 0,98. Conclusión: Los resultados mostraron que el ID es un cuestionario confiable y válido para esta población argentina con esclerodermia.
Objective: the aim of our study was to adapt and to validate theDHI questionnaire in an argentinian population with scleroderma. Methods: For validation, rheumatologists translated to Spanish the original version in French. To evaluate the construct validity, we used thepatient global visual analogue scale (VAS), VAS for questions for the sameactivity, the health assessment questionnaire (HAQ) and the Rodnan. Results: a total of 45 patients with scleroderma were includedin the study. The correlation between the total score of DHI and thepatient global VAS was 0.58, with the HAQ was 0.63 and with Rodnan0.08. The correlation coefficient between the VAS and each group of questions for the same activity in the DHI questionnaire, indicatedgood correlation for the questions that refer to activities of kitchen, aswell as for dressing, for hygiene, and for the office questions. Therewas excellent level of correlation with those related to fine motoractivities. The reproducibility was 0.88 and the reliability was 0.98. Conclusion: The results from this study show the DHI to be a reliableand valid test for this argentinian population with scleroderma.
Scleroderma, Diffuse , Scleroderma, Limited , Scleroderma, Systemic
